ResearcherHumboldt-Universität zu BerlinActive in the last 2 years
Annika Kurreck
Matched on ORCID iD 0000-0002-4352-6788; OpenAlex author ID A5037011093. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 29
2021: 2 papers · 2022: none · 2023: none · 2024: 2 papers
Papers 4
- Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116… Co-author DOI 10.1007/s00432-024-05827-x↗
- Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO … Co-author DOI 10.1007/s00432-024-05954-5↗
- Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma -… Co-author DOI 10.1016/j.ejca.2021.03.036↗
- Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Co-author DOI 10.3389/fonc.2021.670396↗
Closest collaborators
The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dominik Paul Modest · 3 shared papers, 2021–2024 · strength 0.40
- Paper Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin… DOI 10.1007/s00432-024-05827-x↗
- Paper Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with res… DOI 10.1016/j.ejca.2021.03.036↗
- Paper Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. DOI 10.3389/fonc.2021.670396↗
- Helmut Oettle · 3 shared papers, 2021–2024 · strength 0.40
- Paper Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin… DOI 10.1007/s00432-024-05827-x↗
- Paper Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with res… DOI 10.1016/j.ejca.2021.03.036↗
- Paper Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. DOI 10.3389/fonc.2021.670396↗
- Marcus Bahra · 2 shared papers, 2021 · strength 0.24
- Paper Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with res… DOI 10.1016/j.ejca.2021.03.036↗
- Paper Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. DOI 10.3389/fonc.2021.670396↗
- Jana Käthe Striefler · 2 shared papers, 2021 · strength 0.24
- Paper Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with res… DOI 10.1016/j.ejca.2021.03.036↗
- Paper Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. DOI 10.3389/fonc.2021.670396↗
- Marianne Sinn · 2 shared papers, 2021 · strength 0.24
- Paper Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with res… DOI 10.1016/j.ejca.2021.03.036↗
- Paper Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. DOI 10.3389/fonc.2021.670396↗
- Uwe Pelzer · 2 shared papers, 2021 · strength 0.24
- Paper Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with res… DOI 10.1016/j.ejca.2021.03.036↗
- Paper Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. DOI 10.3389/fonc.2021.670396↗
- Hanno B. Riess · 2 shared papers, 2021 · strength 0.24
- Paper Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with res… DOI 10.1016/j.ejca.2021.03.036↗
- Paper Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. DOI 10.3389/fonc.2021.670396↗
- Larissa Henze · 1 shared paper, 2024 · strength 0.16
- Volker Kunzmann · 1 shared paper, 2024 · strength 0.16
- Oliver Waidmann · 1 shared paper, 2024 · strength 0.16
- Volker Heinemann · 1 shared paper, 2024 · strength 0.16
- Janna-Lisa Velthaus · 1 shared paper, 2024 · strength 0.15
- Sabrina Sulzer · 1 shared paper, 2024 · strength 0.15
- Stefanie Hegenberg · 1 shared paper, 2024 · strength 0.15
- Céline Lugnier · 1 shared paper, 2024 · strength 0.15
- Heiko Becker · 1 shared paper, 2024 · strength 0.15
- Maximilian Reichert · 1 shared paper, 2024 · strength 0.15
- Timm M. Reißig · 1 shared paper, 2024 · strength 0.15
- Sebastian Lange · 1 shared paper, 2024 · strength 0.15
- Arndt Vogel · 1 shared paper, 2024 · strength 0.15
- Klara Dorman · 1 shared paper, 2024 · strength 0.15
- David P. Witte · 1 shared paper, 2024 · strength 0.15
- Georg Beyer · 1 shared paper, 2024 · strength 0.15
- Anke Reinacher‐Schick · 1 shared paper, 2024 · strength 0.15
- Christoph Benedikt Westphalen · 1 shared paper, 2024 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.